Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2000; Volume 21(Number 05): 375-384
DOI: 10.1055/s-2000-9400
DOI: 10.1055/s-2000-9400
Economic Issues in Lung Cancer
Further Information
Publication History
Publication Date:
31 December 2000 (online)
ABSTRACT
The purpose of this study is to review the economics of lung cancer management. The economic literature that relates to the diagnosis, treatment, and palliation of lung cancer as well as the pertinent methodological literature were reviewed. Lung cancer treatment is moderately expensive. The overall cost to society is significant given its high incidence. The cost of staging lung cancer can be minimized through the judicious use of diagnostic and staging procedures. The cost-effectiveness of combined modality therapy and palliative chemotherapy for lung cancer appears reasonable when compared with commonly accepted medical interventions. Based on this review, current approaches to lung cancer diagnosis and treatment are, for the most part, cost-effective. Reasons for inconsistent practice patterns in the management of lung cancer in the medical community should be further explored.
KEYWORD
Lung cancer - costs - decision-making
REFERENCES
- 1 Parker S L, Toug T, Bolden S, Wingo P. Cancer statistics 1996. CA Cancer J Clin . 1996; 65 5-27
- 2 National Cancer Institute of Canada. Canadian Cancer Statistics 1997. Toronto, Canada, National Cancer Institute of Canada,
1997
Reference Ris Wihthout Link
- 3 Vergnenègre A, Perol M, Pham E, the GFPC (Group Francais Pneumo Cancérologie). Cost analysis of hospital treatment-two chemotherapeutic regimens for non-surgical non-small cell lung cancer. Lung Cancer . 1996; 14 31-44
- 4 Palmer A J, Brandt A. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: An Italian perspective. Monaldi Arch Chest Dis . 1996; 51 279-288
- 5 Govert J A, Kopita J M, Matchar D, Kussin P S, Samuelson W M. Cost-effectiveness of collecting routine cytologic specimens during fiberoptic bronchoscopy for endoscopically visible lung tumor. Chest . 1996; 109 451-456
- 6 Black W C, Armstrong P, Daniel T M. Cost effectiveness of chest CT in T1N0M0 lung cancer. Radiology . 1988; 167 373-378
- 7 Eddy R J. Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer. J Can Assoc Radiol . 1989; 40 189-193
- 8 The Canadian Lung Oncology Group. Investigation for mediastinal disease in patients with apparently operable lung cancer. Ann Thorac Surgery . 1995; 60 1382-1389
- 9 Gambhir S S, Hoh C K, Phelps M E, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nuc Med . 1996; 37 1428-1436
- 10 Colice G L, Birkmeyer J D, Black W C, Littenberg B, Silvestri G. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest . 1995; 108 1264-1271
- 11 Richardson G E, Venzon D J, Phelps R, Edison M, Brown M, Frame J N, Ihde D C, Johnson B E. Application of an algorithm for staging small-cell lung cancer can save one-third of the initial evaluation costs. Arch Intern Med . 1993; 153 329-337
- 12 Rosenthal M A, Webster P J, Gebski V J, Stuart-Harris R C, Langlands A O, Boyages J. The cost of treating small cell lung cancer. Med J Aust . 1992; 156 605-610
- 13 Evans W K, Will B P, Berthelot J-M, Wolfson M C. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model. Can J Oncol . 1995; 5 408-419
- 14 Goodwin P J, Feld R, Evans W K, Pater J. Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol . 1988; 6 1537-1547
- 15 Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New Engl J Med . 1991; 325 164-170
- 16 Glaspy J A, Bleecker G, Crawford J, Stoller R, Strauss M. The impact of therapy with figrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer . 1993; 29A(suppl 7) S23-S30
- 17 Lyman G H, Lyman C G, Sanderson R A, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst . 1993; 85 488-493
- 18 Nichols C R, Fox E P, Roth B J, Williams S D, Loehrer P J, Einhorn L H. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol . 1994; 12 1245-1250
- 19 Jaakkimainen L, Goodwin P J, Pater J, Warde P, Murray N, Rapp E. Counting the costs of cancer chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol . 1990; 8 1301-1309
- 20 Kennedy W, Reinharz D, Tessier G, Contandriopoulos A-P, Trabut I, Champagne F, Ayoub J. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer. PharmacoEconomics . 1995; 8 316-323
- 21 Evans W K, Will B P, Berthelot J M, Wolfson M C. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer . 1995; 72 1270-1277
- 22 Evans W K, Will B P, Berthelot J M, Wolfson M C. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model. Can J Oncol . 1995; 5 408-419
- 23 Evans W K. Cost-effectiveness of vinorelbine alone or vinorelbine plun cisplatin for stage IV NSCLC. Oncology . 1998; 3 18-26
- 24 Evans W K, Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer . 1996; 32A 2249-2255
- 25 Earle C C, Evans W K. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Cancer Prev Contr . 1997; 1 282-288
- 26 Hillner B E, Smith T J. Overview of economic analysis of Le Chevalier vinorelbine study. Oncology . 1998; 12 14-17
- 27 Smith T J, Hillner B E, Neighbors D M, McSorley P A, Le Chevalier T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol . 1995; 13 2166-2173
- 28 Earle C C, Evans W k. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer . 1999; 80 815-820
- 29 Laupacis A, Feeny D, Detsky A S, Tugwell P X. How attractive does a new technology have to be to warrant adoption with utilization?. <~>Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J . 1992; 146 473-481
- 30 Laupacis A, Feeny D, Detsky A S, Tugwell P X. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J . 1993; 148 927-929
- 31 Bordeleau L, Earle C C, Will B P, Coyle D, Berthelot J-M, Evans W K. A decision-making framework for chemotherapeutic interventions for advanced non-small cell lung cancer. J Natl Cancer Inst. in press;
- 32 Evans W K. An estimate of the cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer. Semin Oncol . 1996; 23 82-89
- 33 Copley-Merriman C, Corral J, King K, Whiteside R, Voi M, Dorr A, McDonald R C. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer. Lung Cancer . 1996; 14 45-61
- 34 Williamson S K, Crowley J J, Livingston R B, Panella T J, Goodwin J W. Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group Study. Invest New Drugs . 1995; 13 67-71
- 35 Evans W K, Will B P, Berthelot J-M, Earle C C. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol . 1997; 15 3038-3048
- 36 Evans W K, Will B P, Berthelot J-M, Wolfson M C. The economics of lung cancer management in Canada. Lung Cancer . 1996; 14 19-29
- 37 Desch C E, Hillner B E, Smith T J. Economic considerations in the care of lung cancer patients. Curr Opin Oncol . 1996; 8 126-132
- 38 Weeks J. Overview of outcomes research and management and its role in oncology practice. Oncology . 1998; 12 11-13
- 39 Smith T J. A piece of mind. Which hat do I wear?. JAMA . 1993; 270 1657-1659
- 40 Smith T J, Hillner B E, Desch C E. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst . 1993; 85 1460-1474
- 41 Raby B, Pater J, Mackillop W J. Does knowledge guide practice?. <~>Another look at the management of non-small-cell lung cancer. J Clin Oncol . 1995; 13 1904-1911